Nitric oxide in neurodegeneration: Potential benefits of non-steroidal anti-inflammatories

Neuroscience Bulletin

Volumn 27, Issue 6, 2011, Pages 366-382

  Doherty, Gayle Helane ^a  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

Alzheimer's disease; Neurodegenerative disease; Neuroinflammation; Nitric oxide; Parkinson's disease

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; IBUPROFEN; INDOMETACIN; NAPROXEN; NIMESULIDE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ALZHEIMER DISEASE; CELL ACTIVATION; CENTRAL NERVOUS SYSTEM; DRUG MECHANISM; ENZYME ACTIVE SITE; ENZYME SYNTHESIS; HISTOPATHOLOGY; HUMAN; MACROGLIA; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NEUROMODULATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; REVIEW;

ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CENTRAL NERVOUS SYSTEM; CYTOKINES; HUMANS; NEURODEGENERATIVE DISEASES; NEURONS; NITRIC OXIDE; PARKINSON DISEASE;

EID: 84856053860     PISSN: 16737067     EISSN: 19958218     Source Type: Journal    
DOI: 10.1007/s12264-011-1530-6     Document Type: Review

References (135)

1. Barbosa RM, Lourenço CF, Santos RM, Pomerleau F, Huettl P, Gerhardt GA, et al. In vivo real-time measurement of nitric oxide in anesthetized rat brain. Methods Enzymol 2008, 441: 351-367.
2. Hon YY, Sun H, Dejam A, Gladwin MT. Characterization of erythrocytic uptake and release and disposition pathways of nitrite, nitrate, methemoglobin, and iron-nitrosyl hemoglobin in the human circulation. Drug Metab Dispos 2010, 38(10): 1707-1713.
3. Nathan C. Inducible nitric oxide synthase: what difference does it make? J Clin Invest 1997, 100(10): 2417-2423. (Pubitemid 27514879)
4. Springall DR, Riveros-Moreno V, Buttery L, Suburo A, Bishop AE, Merrett M, et al. Immunological detection of nitric oxide synthase(s) in human tissues using heterologous antibodies suggesting different isoforms. Histochemistry 1992, 98(4): 259-266.
5. Nakane M, Schmidt HH, Pollock JS, Forstermann U, Murad F. Cloned human brain nitric oxide synthase is highly expressed in skeletal muscle. FEBS Lett 1993, 316(2): 175-180. (Pubitemid 23025053)
6. Kobzik L, Reid MB, Bredt DS, Stamler JS. Nitric oxide in skeletal muscle. Nature 1994, 372: 546-548. (Pubitemid 24368535)
7. Islam MS, Matsumoto M, Tsuchida K, Oka T, Kanouchi H, Suzuki S. Immunohistochemical localization of nitric oxide synthase (NOS) in mouse mammary gland during reproductive cycle. J Vet Med Sci 2009, 71(7): 945-949.
8. Park S, Harrison-Bernard LM. Augmented renal vascular nNOS and renin protein expression in angiotensin type 1 receptor null mice. J Histochem Cytochem 2008, 56(4): 401-414. (Pubitemid 351429807)
9. Kim SO, Song SH, Hwang EC, Park KS, Kwon DD, Ahn KY, et al. The expression of AQP1 and eNOS in menopausal rat urinary bladder. Int Neurourol J 2010, 14(2): 78-85.
10. Endo D, Yamamoto Y, Yamaguchi-Yamada M, Nakamuta N, Taniguchi K. Localization of eNOS in the olfactory epithelium of the rat. J Vet Med Sci 2011, 73(4): 423-430.
11. Park CS, Krishna G, Ahn MS, Kang JH, Chung WG, Kim DJ, et al. Differential and constitutive expression of neuronal, inducible, and endothelial nitric oxide synthase mRNAs and proteins in pathologically normal human tissues. Nitric Oxide 2000, 4(5): 459-471.
12. Saha RN, Pahan K. Signals for the induction of nitric oxide synthase in astrocytes. Neurochem Int 2006, 49(2): 154-163. (Pubitemid 43867073)
13. Ayajiki K, Kindermann M, Hecker M, Fleming I, Busse R. Intracellular pH and tyrosine phosphorylation but not calcium determine shear stress-induced nitric oxide production in native endothelial cells. Circ Res 1996, 78: 750-758. (Pubitemid 26131358)
14. Daniel H, Hemart N, Jaillard D, Crepel F. Long-term depression requires nitric oxide and guanosine 3′:5′ cyclic monophosphate production in rat cerebellar Purkinje cells. Eur J Neurosci 1993, 5(8): 1079-1082. (Pubitemid 23239794)
15. Scott TR, Bennett MR. The effect of nitric oxide on the efficacy of synaptic transmission through the chick ciliary ganglion. Br J Pharmacol 1993, 110(2): 627-632. (Pubitemid 23279270)
16. Schuman EM, Meffert MK, Schulman H, Madison DV. An ADP-ribosyltransferase as a potential target for nitric oxide action in hippocampal long-term potentiation. Proc Natl Acad Sci U S A 1994, 91(25): 11958-11962. (Pubitemid 24368583)
17. Jian K, Chen M, Cao X, Zhu XH, Fung ML, Gao TM. Nitric oxide modulation of voltage-gated calcium current by S-nitrosylation and cGMP pathway in cultured rat hippocampal neurons. Biochem Biophys Res Commun 2007, 359(3): 481-485. (Pubitemid 46898976)
18. Pyriochou A, Papapetropoulos A. Soluble guanylate cyclase: more secrets revealed. Cell Signal 2005, 17(4): 407-413. (Pubitemid 39643059)
19. Mannick JB, Schonhoff C, Papeta N, Ghafourifar P, Szibor M, Fang K, et al. S-Nitrosylation of mitochondrial caspases. J Cell Biol 2001, 154(6): 1111-1116. (Pubitemid 34286189)
20. Prast H, Philippu A. Nitric oxide as modulator of neuronal function. Prog Neurobiol 2001, 64(1): 51-68. (Pubitemid 32201889)
21. Wilson GW, Garthwaite J. Hyperpolarization-activated ion channels as targets for nitric oxide signalling in deep cerebellar nuclei. Eur J Neurosci 2010, 31(11): 1935-1945.
22. Ciani E, Virgili M, Contestabile A. Akt pathway mediates a cGMP dependent survival role of nitric oxide in cerebellar granule neurones. J Neurochem 2002, 81(2): 218-228. (Pubitemid 34809347)
23. Martin LJ, Adams NA, Pan Y, Price A, Wong M. The mitochondrial permeability transition pore regulates nitric oxide-mediated apoptosis of neurons induced by target deprivation. J Neurosci 2011, 31(1): 359-370.
24. Lin DT, Fretier P, Jiang C, Vincent SR. Nitric oxide signaling via cGMP-stimulated phosphodiesterase in striatal neurons. Synapse 2010, 64(6): 460-466.
25. Wen J, Ribeiro R, Zhang Y. Specific PKC isoforms regulate LPS-stimulated iNOS induction in murine microglial cells. J Neuroinflammation 2011, 8: 38.
26. Zhang M, Zhou J, Marshall B, Xin H, Atherton SS. Lack of iNOS facilitates MCMV spread in the retina. Invest Ophthalmol Vis Sci 2007, 48(1): 285-292. (Pubitemid 47251415)
27. Ono K, Suzuki H, Sawada M. Delayed neural damage is induced by iNOS-expressing microglia in a brain injury model. Neurosci Lett 2010, 473(2): 146-150.
28. Prüss H, Prass K, Ghaeni L, Milosevic M, Muselmann C, Freyer D, et al. Inducible nitric oxide synthase does not mediate brain damage after transient focal cerebral ischemia in mice. J Cereb Blood Flow Metab 2008, 28(3): 526-539. (Pubitemid 351304264)
29. Thippeswamy T, Jain RK, Mumtaz N, Morris R. Inhibition of neuronal nitric oxide synthase results in neurodegenerative changes in the axotomised dorsal root ganglion neurons: evidence for a neuroprotective role of nitric oxide in vivo. Neurosci Res 2001, 40 (1): 37-44. (Pubitemid 32328236)
30. Thippeswamy T, McKay JS, Morris R. Bax and caspases are inhibited by endogenous nitric oxide in dorsal root ganglion neurons in vitro. Eur J Neurosci 2001, 14 (8): 1229-1236. (Pubitemid 35463730)
31. Kim PK, Kwon YG, Chung HT, Kim YM. Regulation of caspases by nitric oxide. Ann N Y Acad Sci 2002, 962: 42-52. (Pubitemid 34592298)
32. Gross SS, Wolin MS. Nitric oxide: pathophysiological mechanisms. Annu Rev Physiol 1995, 57: 737-769.
33. Dawson VL, Dawson TM. Nitric oxide in neurodegeneration. Prog Brain Res 1998, 118: 215-229. (Pubitemid 28530669)
34. Figueroa S, Oset-Gasque MJ, Arce C, Martinez-Honduvilla CJ, Gonzalez MP. Mitochondrial involvement in nitric oxide-induced cellular death in cortical neurons in culture. J Neurosci Res 2006, 83 (3): 441-449. (Pubitemid 43184407)
35. Gutierrez-Martin Y, Martin-Romero FJ, Henao F, Gutierrez-Merino C. Alteration of cytosolic free calcium homeostasis by SIN-1: high sensitivity of L type Ca2+ channels to extracellular oxidative/nitrosative stress in cerebellar granule cells. J Neurochem 2005, 92 (4): 973-989. (Pubitemid 40229569)
36. Oldreive CE, Gaynor S, Doherty GH. Developmental changes in the response of murine cerebellar granule cells to nitric oxide. Neurochem Inter 2008, 52: 1394-1401.
37. Oldreive CE, Gaynor S, Doherty GH. Effects of nitric oxide on the survival and neuritogenesis of cerebellar Purkinje neurons. J Mol Neurosci 2011. DOI 10.1007/s12031-011-9590-7.
38. Behl C, Davis JB, Klier FG, Schubert D. Amyloid beta peptide induces necrosis rather than apoptosis. Brain Res 1994, 645(1-2): 253-264. (Pubitemid 24140132)
39. McBride AG, Borutaité V, Brown GC. Superoxide dismutase and hydrogen peroxide cause rapid nitric oxide breakdown, peroxynitrite production and subsequent cell death. Biochim Biophys Acta 1999, 1454(3): 275-288. (Pubitemid 29378375)
40. Brown GC, Borutaite V. Nitric oxide inhibition of mitochondrial respiration and its role in cell death. Free Radic Biol Med 2002, 33(11): 1440-1450. (Pubitemid 35351587)
41. Bal-Price A, Brown GC. Nitric oxide-induced necrosis and apoptosis in PC12 cells mediated by mitochondria. J Neurochem 2000, 75(4): 1455-1464.
42. Almeida A, Almeida J, Bolaños JP, Moncada S. Different responses of astrocytes and neurons to nitric oxide: the role of glycolytically generated ATP in astrocyte protection. Proc Natl Acad Sci U S A 2001, 98(26): 15294-15299. (Pubitemid 34014008)
43. Ishitani R, Chuang DM. Glyceraldehyde-3-phosphate dehydrogenase antisense oligodeoxynucleotides protect against cytosine arabinonucleoside-induced apoptosis in cultured cerebellar neurons. Proc Natl Acad Sci U S A 1996, 93(18): 9937-9941. (Pubitemid 26296713)
44. Sawa A, Khan AA, Hester LD, Snyder SH. Glyceraldehyde-3-phosphate dehydrogenase: nuclear translocation participates in neuronal and nonneuronal cell death. Proc Natl Acad Sci U S A 1997, 94(21): 11669-11674. (Pubitemid 27451056)
45. Hara MR, Thomas B, Cascio MB, Bae BI, Hester LD, Dawson VL, et al. Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc Natl Acad Sci U S A 2006, 103(10): 3887-3889. (Pubitemid 43376650)
46. He J, Kang H, Yan F, Chen C. The endoplasmic reticulum-related events in S-nitrosoglutathione-induced neurotoxicity in cerebellar granule cells. Brain Res 2004, 1015(1-2): 25-33. (Pubitemid 38829733)
47. Borutaite V, Morkuniene R, Brown GC. Nitric oxide donors, nitrosothiols and mitochondrial respiration inhibitors induce caspase activation by different mechanisms. FEBS Lett 2000, 467(2-3): 155-159. (Pubitemid 30081725)
48. Bonthius DJ, Luong T, Bonthius NE, Hostager BS, Karacay B. Nitric oxide utilizes NF-kappaB to signal its neuroprotective effect against alcohol toxicity. Neuropharmacology 2009, 56(3): 716-731.
49. Gao F, Gao E, Yue TL, Ohlstein EH, Lopez BL, Christopher TA, et al. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation 2002, 105(12): 1497-1502. (Pubitemid 34263284)
50. Murphy PR, Limoges M, Dodd F, Boudreau RT, Too CK. Fibroblast growth factor-2 stimulates endothelial nitric oxide synthase expression and inhibits apoptosis by a nitric oxide-dependent pathway in Nb2 lymphoma cells. Endocrinology 2001, 142(1): 81-88. (Pubitemid 32183668)
51. Reynolds MR, Berry RW, Binder LI. Nitration in neurodegeneration: deciphering the "Hows" "nYs". Biochemistry 2007, 46(25): 7325-7336. (Pubitemid 46986359)
52. Ghafourifar P, Schenk U, Klein SD, Richter C. Mitochondrial nitric-oxide synthase stimulation causes cytochrome c release from isolated mitochondria. Evidence for intramitochondrial peroxynitrite formation. J Biol Chem 1999, 274(44): 31185-31188.
53. Cidad P, Almeida A, Bolaños JP. Inhibition of mitochondrial respiration by nitric oxide rapidly stimulates cytoprotective GLUT3-mediated glucose uptake through 5′-AMP-activated protein kinase. Biochem J 2004, 384: 629-636. (Pubitemid 40018977)
54. Fehrenbach H, Zimmermann G, Starke E, Bratu VA, Conrad D, Yildirim AO, et al. Nitrogen dioxide induces apoptosis and proliferation but not emphysema in rat lungs. Thorax 2007, 62(5): 438-446. (Pubitemid 46698395)
55. Dawson VL, Dawson TM, London ED, Bredt DS, Snyder SH. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci U S A 1991, 88(14): 6368-6371. (Pubitemid 21914947)
56. Alzheimer A. Ueber eine eigenartige. Erkrankung der Hirnrinde Allg Z Psychiat 1907, 64: 146-148.
57. Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". Clin Anat 1995, 8(6): 429-431.
58. Zilka N, Novak M. The tangled story of Alois Alzheimer. Bratisl Lek Listy 2006, 107(9-10): 343-345.
59. Doherty G. Metabolic influences on neurological disorders: Focus on homocysteine in Alzheimer's disease. In: Doherty GH (Ed.). Metabolic Influences on Neurological Disorders. Kerala: Transworld Research Network, 2010: 1-12.
60. Good PF, Werner P, Hsu A, Olanow CW, Perl DP. Evidence of neuronal oxidative damage in Alzheimer's disease. Am J Pathol 1996, 149(1): 21-28. (Pubitemid 26230974)
61. Uehara T, Nakamura T, Yao D, Shi ZQ, Gu Z, Ma Y, et al. S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature 2006, 441(7092): 513-517. (Pubitemid 44050153)
62. Honjo Y, Ito H, Horibe T, Takahashi R, Kawakami K. Protein disulfide isomerase-immunopositive inclusions in patients with Alzheimer disease. Brain Res 2010, 1349: 90-96.
63. Gu Z, Nakamura T, Lipton SA. Redox reactions induced by nitrosative stress mediate protein misfolding and mitochondrial dysfunction in neurodegenerative diseases. Mol Neurobiol 2010, 41(2-3): 55-72.
64. Keil U, Bonert A, Marques CA, Scherping I, Weyermann J, Strosznajder JB, et al. Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis. J Biol Chem 2004, 279(48): 50310-50320. (Pubitemid 39577847)
65. Sparrow JR. Inducible nitric oxide synthase in the central nervous system. J Mol Neurosci 1994-1995, 5(4): 219-229.
66. Combs CK, Karlo JC, Kao SC, Landreth GE. beta-Amyloid stimulation of microglia and monocytes results in TNF alpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci 2001, 21(4): 1179-1188. (Pubitemid 32128763)
67. Yan SD, Stern D, Kane MD, Kuo YM, Lampert HC, Roher AE. RAGE-Abeta interactions in the pathophysiology of Alzheimer's disease. Restor Neurol Neurosci 1998, 12(2-3): 167-173. (Pubitemid 28368298)
68. Jana M, Palencia CA, Pahan K. Fibrillar amyloid-beta peptides activate microglia via TLR2: implications for Alzheimer's disease. J Immunol 2008, 181(10): 7254-7262.
69. Doherty GH. Developmental switch in the effects of TNF alpha on ventral midbrain dopaminergic neurons. Neurosci Res 2007, 57(2): 296-305. (Pubitemid 46188485)
70. Bongiorno MR, Pistone G, Doukaki S, Aricò M. Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis. Dermatol Ther 2008, 21 (Suppl 2): S15-20.
71. Tobinick E, Gross H, Weinberger A, Cohen H. TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. Med Gen Med 2006, 8: 25.
72. Mrak RE, Griffin WST. Interleukin-1, neuroinflammation, and Alzheimer's disease. Neurobiol Aging 2001, 22: 903-908. (Pubitemid 34066557)
73. Rogers JT, Leiter LM, McPhee J, Cahill CM, Zhan S, Potter H, et al. Translation of the Alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5′-untranslated region sequences. J Biol Chem 1999, 274(10): 6421-6431. (Pubitemid 29111057)
74. Sheng JG, Jones RA, Zhou XQ, McGinness JM, Van Eldik LJ, Mrak RE, et al. Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's disease: potential significance for tau protein phosphorylation. Neurochem Inter 2001, 39: 341-348. (Pubitemid 32907398)
75. Griffin WST, Mrak RE. Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer's disease. J Leukocyte Biol 2002, 72: 233-238.
76. Lio D, Licastro F, Scola L, Chiappelli M, Grimaldi LM, Crivello A, et al. Interleukin-10 promoter polymorphism in sporadic Alzheimer's disease. Genes Immun 2003, 4: 234-238. (Pubitemid 38967602)
77. Ogawa O, Umegaki H, Sumi D, Hayashi T, Nakamura A, Thakur NK, et al. Inhibition of inducible nitric oxide synthase gene expression by indomethacin or ibuprofen in beta-amyloid proteinstimulated J774 cells. Eur J Pharmacol 2000, 408(2): 137-141.
78. Asanuma M, Nishibayashi-Asanuma S, Miyazaki I, Kohno M, Ogawa N. Neuroprotective effects of non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals. J Neurochem 2001, 76(6): 1895-1904. (Pubitemid 32221130)
79. Thomas B, Beal MF. Parkinson's disease. Hum Mol Genet 2007, 16: R183-194.
80. Betarbet R, Sherer TB, Greenamyre JT. Animal models of Parkinson's disease. Bioessays 2002, 24(4): 308-318. (Pubitemid 34305686)
81. Doherty GH, Oldreive C, Harvey J. Neuroprotective actions of leptin on central and peripheral neurons in vitro. Neuroscience 2008, 154(4): 1297-1307.
82. Mandir AS, Przedborski S, Jackson-Lewis V, Wang ZQ, Simbulan-Rosenthal CM, Smulson ME, et al. Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc Natl Acad Sci U S A 1999, 96(10): 5774-5779. (Pubitemid 29234694)
83. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999, 5(12): 1403-1409.
84. Di Matteo V, Pierucci M, Benigno A, Crescimanno G, Esposito E, Di Giovanni G. Involvement of nitric oxide in nigrostriatal dopaminergic system degeneration: a neurochemical study. Ann N Y Acad Sci 2009, 1155: 309-315.
85. Chung KK, Thomas B, Li X, Pletnikova O, Troncoso JC, Marsh L, et al. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science 2004, 304(5675): 1328-1331. (Pubitemid 38697430)
86. Wang C, Ko HS, Thomas B, Tsang F, Chew KC, Tay SP, et al. Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function. Hum Mol Genet 2005, 14(24): 3885-3897. (Pubitemid 43020090)
87. Fang J, Nakamura T, Cho DH, Gu Z, Lipton SA. S-nitrosylation of peroxiredoxin 2 promotes oxidative stress-induced neuronal cell death in Parkinson's disease. Proc Natl Acad Sci U S A 2007, 104(47): 18742-18747. (Pubitemid 350210767)
88. Tsang AH, Lee YI, Ko HS, Savitt JM, Pletnikova O, Troncoso JC, et al. S-nitrosylation of XIAP compromises neuronal survival in Parkinson's disease. Proc Natl Acad Sci U S A 2009, 106(12): 4900-4905.
89. Lee SJ, Kim DC, Choi BH, Ha H, Kim KT. Regulation of p53 by activated protein kinase C-delta during nitric oxide-induced dopaminergic cell death. J Biol Chem 2006, 281(4): 2215-2224. (Pubitemid 43845812)
90. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38(8): 1285-1291.
91. Zhou Y, Wang Y, Kovacs M, Jin J, Zhang J. Microglial activation induced by neurodegeneration: a proteomic analysis. Mol Cell Proteomics 2005, 4(10): 1471-1479. (Pubitemid 41555473)
92. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002, 22(5): 1763-1771. (Pubitemid 35386294)
93. Ferger B, Leng A, Mura A, Hengerer B, Feldon J. Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. J Neurochem 2004, 89(4): 822-833. (Pubitemid 38684730)
94. Shen S, Yu S, Binek J, Chalimoniuk M, Zhang X, Lo SC, et al. Distinct signaling pathways for induction of type II NOS by IFN gamma and LPS in BV-2 microglial cells. Neurochem Int 2005, 47(4): 298-307. (Pubitemid 40943472)
95. Miller RL, James-Kracke M, Sun GY, Sun AY. Oxidative and inflammatory pathways in Parkinson's disease. Neurochem Res 2009, 34(1): 55-65.
96. Martín-Moreno AM, Reigada D, Ramírez BG, Mechoulam R, Innamorato N, Cuadrado A, et al. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease. Mol Pharmacol 2011, 79(6): 964-973.
97. Hoozemans JJ, Rozemuller AJ, Janssen I, De Groot CJ, Veerhuis R, Eikelenboom P. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol 2001, 101(1): 2-8. (Pubitemid 32124493)
98. Yasojima K, Schwab C, McGeer EG, McGeer PL. Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res 1999, 830(2): 226-236. (Pubitemid 29297950)
99. Andreasson KI, Savonenko A, Vidensky S, Goellner JJ, Zhang Y, Shaffer A, et al. Age-dependent cognitive deficits and neuronal apoptosis in cyclooxygenase-2 transgenic mice. J Neurosci 2001, 21(20): 8198-8209. (Pubitemid 32952775)
100. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997, 272(6): 3406-3410.
101. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391(6662): 82-86. (Pubitemid 28079219)
102. Kitamura Y, Kakimura J, Matsuoka Y, Nomura Y, Gebicke-Haerter PJ, Taniguchi T. Activators of peroxisome proliferator-activated receptor-gamma (PPAR gamma) inhibit inducible nitric oxide synthase expression but increase heme oxygenase-1 expression in rat glial cells. Neurosci Lett 1999, 262(2): 129-132. (Pubitemid 29130305)
103. Tortosa E, Avila J, Pérez M. Acetylsalicylic acid decreases tau phosphorylation at serine 422. Neurosci Lett 2006, 396(1): 77-80. (Pubitemid 43233792)
104. Zhou Y, Su Y, Li B, Liu F, Ryder JW, Wu X, et al. Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science 2003, 302(5648): 1215-1217. (Pubitemid 37421027)
105. Bourne KZ, Ferrari DC, Lange-Dohna C, Rossner S, Wood TG, Perez-Polo JR. Differential regulation of BACE1 promoter activity by nuclear factor-kappaB in neurons and glia upon exposure to beta-amyloid peptides. J Neurosci Res 2007, 85(6): 1194-1204. (Pubitemid 46724363)
106. Lleó A, Berezovska O, Herl L, Raju S, Deng A, Bacskai BJ, et al. Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat Med 2004, 10(10): 1065-1066. (Pubitemid 39424866)
107. In't Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, et al. Do non-steroidal anti-inflammatory drugs reduce the risk of Alzheimer's Disease? New Eng J Med 2001, 345(21): 1515-1521. (Pubitemid 33144916)
108. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997, 48(3): 626-632. (Pubitemid 27120096)
109. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993, 43(8): 1609-1611. (Pubitemid 23230557)
110. ADAPT Research Group, Lyketsos CG, Breitner JC, Green RC, Martin BK, Meinert C, et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 2007, 68(21): 1800-1808. (Pubitemid 46791392)
111. ADAPT Research Group, Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, et al. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 2008, 65(7): 896-905. (Pubitemid 352008472)
112. Gagne JJ, Power MC. Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 2010, 74(12): 995-1002.
113. Kumar P, Kumar A. Effect of lycopene and epigallocatechin-3-gallate against 3-nitropropionic acid induced cognitive dysfunction and glutathione depletion in rat: a novel nitric oxide mechanism. Food Chem Toxicol 2009, 47(10): 2522-2530.
114. Kumar P, Kumar A. Protective effect of hesperidin and naringin against 3-nitropropionic acid induced Huntington's like symptoms in rats: possible role of nitric oxide. Behav Brain Res 2010, 206(1): 38-46.
115. Basso M, Samengo G, Nardo G, Massignan T, D'Alessandro G, Tartari S, et al. Characterization of detergent-insoluble proteins in ALS indicates a causal link between nitrative stress and aggregation in pathogenesis. PLoS One 2009, 4(12): e8130.
116. Doherty GH. How can we prevent neuronal apoptosis? In: Schmid CJ, Wolfe JL (Eds.). Neuronal Cell Apoptosis. Nova Science Publishers Inc., 2011.
117. Bennet JP. Biochemical pathology and pharmacology of Parkinson's disease. In: Stern MB, Hurtig HI (Eds.). The Comprehensive Management of Parkinson's Disease. New York: PMA Publishing, 1988: 63-76.
118. Shaftel SS, Griffin WS, O'Banion MK. The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J Neuroinflammation 2008, 5: 7.
119. Lukiw WJ, Bazan NG. Cyclooxygenase 2 RNA message abundance, stability, and hypervariability in sporadic Alzheimer neocortex. J Neurosci Res 1997, 50(6): 937-945. (Pubitemid 28034648)
120. Yermakova AV, O'Banion MK. Downregulation of neuronal cyclooxygenase-2 expression in end stage Alzheimer's disease. Neurobiol Aging 2001, 22(6): 823-836. (Pubitemid 34066549)
121. Combrinck M, Williams J, De Berardinis MA, Warden D, Puopolo M, Smith AD, et al. Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2006, 77(1): 85-88. (Pubitemid 43022699)
122. Montine TJ, Sidell KR, Crews BC, Markesbery WR, Marnett LJ, Roberts LJ 2nd, et al. Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology 1999, 53(7): 1495-1498. (Pubitemid 29491943)
123. Wang F, Zhai H, Huang L, Li H, Xu Y, Qiao X, et al. Aspirin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity in primary midbrain cultures. J Mol Neurosci 2011. [Epub ahead of print]
124. Moghaddam HF, Hemmati A, Nazari Z, Mehrab H, Abid KM, Ardestani MS. Effects of aspirin and celecoxib on rigidity in a rat model of Parkinson's disease. Pak J Biol Sci 2007, 10(21): 3853-3858. (Pubitemid 350219178)
125. Maharaj DS, Saravanan KS, Maharaj H, Mohanakumar KP, Daya S. Acetaminophen and aspirin inhibit superoxide anion generation and lipid peroxidation, and protect against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Neurochem Int 2004, 44(5): 355-360. (Pubitemid 37485867)
126. Beeri MS, Schmeidler J, Lesser GT, Maroukian M, West R, Leung S, et al. Corticosteroids, but not NSAIDs, are associated with less Alzheimer neuropathology. Neurobiol Aging 2011. [Epub ahead of print]
127. Sonnen JA, Larson EB, Walker RL, Haneuse S, Crane PK, Gray SL, et al. Nonsteroidal anti-inflammatory drugs are associated with increased neuritic plaques. Neurology 2010, 75(13): 1203-1210.
128. Li Z, Wang Y, Xie Y, Yang Z, Zhang T. Protective effects of exogenous hydrogen sulfide on neurons of hippocampus in a rat model of brain ischemia. Neurochem Res 2011. [Epub ahead of print]
129. Hu LF, Lu M, Tiong CX, Dawe GS, Hu G, Bian JS. Neuroprotective effects of hydrogen sulfide on Parkinson's disease rat models. Aging Cell 2010, 9(2): 135-146.
130. Gong QH, Wang Q, Pan LL, Liu XH, Huang H, Zhu YZ. Hydrogen sulfide attenuates lipopolysaccharide-induced cognitive impairment: a pro-inflammatory pathway in rats. Pharmacol Biochem Behav 2010, 96(1): 52-58.
131. Lee M, Sparatore A, Del Soldato P, McGeer E, McGeer PL. Hydrogen sulfide-releasing NSAIDs attenuate neuroinflammation induced by microglial and astrocytic activation. Glia 2010, 58(1): 103-113.
132. Endoh M, Maiese K, Wagner J. Expression of the inducible form of nitric oxide synthase by reactive astrocytes after transient global ischemia. Brain Res 1994, 651(1-2): 92-100. (Pubitemid 24222853)
133. Czlonkowska A, Kohutnicka M, Kurkowska-Jastrzebska I, Czlonkowski A. Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model. Neurodegeneration 1996, 5(2): 137-143. (Pubitemid 26248603)
134. Cicchetti F, Brownell AL, Williams K, Chen YI, Livni E, Isacson O. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 2002, 15(6): 991-998. (Pubitemid 35463634)
135. Sherer TB, Betarbet R, Kim JH, Greenamyre JT. Selective microglial activation in the rat rotenone model of Parkinson's disease. Neurosci Lett 2003, 341(2): 87-90. (Pubitemid 36398476)